Skip to main content
. 2021 Oct 14;22(20):11057. doi: 10.3390/ijms222011057

Figure 5.

Figure 5

Combination of cetuximab with TLR2 agonists induces profound pro-inflammatory responses by PBMCs. ADCC experiments with the HNSCC cell lines VU-SCC-096 (black bars) and UM-SCC-47 (grey bars) were performed with PBMCs in the absence or presence of cetuximab (0.5 µg/mL) and/or Pam3CSK4 (5 µg/mL). After 24 h, supernatants were harvested and used for (A) cytokine and (B) chemokine analysis. Bars represent mean ± SD; n = 2; ** p < 0.01; *** p < 0.001; **** p < 0.0001; ns = not significant.